Keywords: novartis, simulect, gets, cpmp, backing, antibody-based, drug

Novartis' Simulect Gets CPMP Backing

Article | 30 June 1998

Novartis' antibody-based drug for the prevention of rejection in solidorgan transplants, Simulect (basiliximab), has been recommended for approval by the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Novartis

Go to company listing

Related Drugs

Basiliximab

Simulect

Go to drug listing